MX2022004564A - Tienopirimidonas como inhibidores de trpa1. - Google Patents

Tienopirimidonas como inhibidores de trpa1.

Info

Publication number
MX2022004564A
MX2022004564A MX2022004564A MX2022004564A MX2022004564A MX 2022004564 A MX2022004564 A MX 2022004564A MX 2022004564 A MX2022004564 A MX 2022004564A MX 2022004564 A MX2022004564 A MX 2022004564A MX 2022004564 A MX2022004564 A MX 2022004564A
Authority
MX
Mexico
Prior art keywords
thienopyrimidones
trpa1 inhibitors
same
diseases
inhibitors
Prior art date
Application number
MX2022004564A
Other languages
English (en)
Inventor
Georg Dahmann
Joerg P Hehn
Jens Willwacher
Martin Thomas Fleck
Florian Paul Christian Binder
Annekatrin Charlotte Heimann
Uta Friederike Lessel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022004564A publication Critical patent/MX2022004564A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a tienopirimidinonas y a su uso como inhibidores de la actividad de TRPA1, a composiciones farmacéuticas que las contienen, y a métodos para usarlas como agentes para el tratamiento y/o la prevención de enfermedades fibróticas, enfermedades inflamatorias y autoinmunitarias y enfermedades relacionadas con el SNC. (ver Fórmula).
MX2022004564A 2019-10-15 2020-10-14 Tienopirimidonas como inhibidores de trpa1. MX2022004564A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203173 2019-10-15
PCT/EP2020/078855 WO2021074197A1 (en) 2019-10-15 2020-10-14 Thienopyrimidones as trpa1 inhibitors

Publications (1)

Publication Number Publication Date
MX2022004564A true MX2022004564A (es) 2022-05-06

Family

ID=68289874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004564A MX2022004564A (es) 2019-10-15 2020-10-14 Tienopirimidonas como inhibidores de trpa1.

Country Status (14)

Country Link
US (2) US20210107919A1 (es)
EP (1) EP4045144A1 (es)
JP (1) JP7354438B2 (es)
KR (1) KR20220084127A (es)
CN (1) CN114945408B (es)
AR (1) AR120221A1 (es)
AU (1) AU2020366678A1 (es)
BR (1) BR112022003729A2 (es)
CA (1) CA3153115A1 (es)
CL (1) CL2022000757A1 (es)
IL (1) IL292095A (es)
MX (1) MX2022004564A (es)
TW (1) TW202128705A (es)
WO (1) WO2021074197A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
MY159059A (en) * 2010-12-20 2016-12-15 Glenmark Pharmaceuticals Sa 2-amino-4-arylthiazole compounds as trpa1 antagonists
BR112013032025A2 (pt) * 2011-06-13 2016-12-20 Glenmark Pharmaceutical S A antagonistas trpa1, compostos ou seus sais farmaceuticamente aceitáveis, métodos para reduzir a quantidade de eosinófilos ou neutrófilos e/ou aumentar fev1 em indivíduo com distúrbio respiratório, para tratar distúrbio respiratório em indivíduo e/ou para identificar antagonista trpa1, usos de quantidade eficaz de antagonista trpa1, e composição farmacêutica para administração por inalação
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
US20170313719A1 (en) * 2014-11-18 2017-11-02 Emory University Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
WO2017060488A1 (en) * 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists

Also Published As

Publication number Publication date
BR112022003729A2 (pt) 2022-05-31
US20210107919A1 (en) 2021-04-15
AR120221A1 (es) 2022-02-02
CN114945408B (zh) 2024-04-16
US11578080B2 (en) 2023-02-14
KR20220084127A (ko) 2022-06-21
CL2022000757A1 (es) 2023-01-20
WO2021074197A1 (en) 2021-04-22
JP2022551956A (ja) 2022-12-14
CN114945408A (zh) 2022-08-26
AU2020366678A1 (en) 2022-03-31
IL292095A (en) 2022-06-01
CA3153115A1 (en) 2021-04-22
TW202128705A (zh) 2021-08-01
EP4045144A1 (en) 2022-08-24
US20210395267A1 (en) 2021-12-23
JP7354438B2 (ja) 2023-10-02

Similar Documents

Publication Publication Date Title
MX2022002465A (es) Inhibidores de kras g12d.
AU2018236800B2 (en) DNA-PK inhibitors
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
CR20220325A (es) Fluoroalquil-oxadiazoles y sus usos
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
AU2024202525A1 (en) Benzimidazolone derived inhibitors of BCL6
ZA201904522B (en) Heterocyclic inhibitors of mct4
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
MX2018001756A (es) Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
EP3906241A4 (en) INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENT
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
MX2022004564A (es) Tienopirimidonas como inhibidores de trpa1.